Generated Narrative: CodeSystem cdsi-observation-codes This code system http://fhirfli.dev/fhir/ig/cicada/CodeSystem/cdsi-observation-codes defines the following codes: Code Definition 001 Patient seeks protection 002 Undergoing elective splenectomy 003 Immunocompromised 004 Recipient of a hematopoietic stem cell transplant 005 Hepatitis C virus infection 006 Receives clotting factor concentrates 007 Pregnant 008 Travel to an area of active cholera transmission 009 Breastfeeding 010 Cerebrospinal fluid leaks 011 Cochlear implants 012 Family history of altered immunocompetence 013 Severe Combined Immunodeficiency [SCID] 014 Diabetes 015 Chronic liver disease 016 Chronic heart disease 017 Chronic lung disease 018 Laboratory Evidence of Immunity or confirmation of Hepatitis A disease 019 Laboratory Evidence of Immunity or confirmation of Hepatitis B disease 020 Laboratory Evidence of Immunity for Measles 021 Laboratory Evidence of Immunity for Mumps 022 Laboratory Evidence of Immunity for Rubella 023 Laboratory Evidence of Immunity or confirmation of Varicella disease 024 Healthcare provider verified history of or diagnosis of Varicella 025 Healthcare provider verified history or diagnosis of Herpes Zoster 026 Persons with perinatal HIV infection who do not have evidence of severe immunosuppression and who were vaccinated with MMR before establishment of antiviral therapy [ART] 027 Asthma 028 Intussusception 029 Acute gastroenteritis 030 Acute febrile illness 031 Tuberculosis 032 Dialysis patient 033 Taken influenza antiviral medications within the previous 48 hours 034 Receiving long-term aspirin therapy 035 Antimicrobial or antimalarial taken within 72 hours 036 Men who have sex with men 037 Not in a long-term, mutually monogamous relationship 038 Sex partner of Hepatitis B surface antigen-positive persons 039 Receives treatment for STD 040 Illicit drug use 041 Illicit injection drug use 042 Smoke cigarettes 043 Alcoholism 044 Anticipate close personal contact with international adoptee 045 Travel to country with a Yellow Fever vaccination entry requirement 046 College students living in residence halls 047 Resident of area at risk for exposure to the disease 048 Travelling Internationally 049 Working with Hepatitis A virus in research setting 050 Microbiologists routinely exposed to Neisseria meningitidis 051 Microbiology laboratorians who work frequently with S. typhi 052 Laboratory personnel who might be exposed to YFV 053 Rabies researchers 054 Laboratory workers who handle specimens that might contain polioviruses 055 Health care personnel 056 Health-care workers who have close contact with patients who might be excreting wild polioviruses 057 Public safety worker exposed to blood or infection body fluids 058 Staff of institution for persons with developmental disabilities 059 Occupational exposure for Hepatitis A 060 Veterinarians and their staff 061 Animal handlers 062 Persons whose activities bring them into frequent contact with rabies virus or potentially rabid animals 063 Post secondary student 064 Military recruits 065 Client of institution for persons with developmental disabilities 066 Chronic renal failure 068 In drug abuse treatment and prevention facility 069 In correctional facility 070 Persons at risk during an outbreak 071 Household contact with hepatitis B surface antigen-positive persons 072 Intimate exposure to a documented S. typhi carrier 073 Household and close contacts of immunocompromised persons 074 Negative serological screening for varicella 075 Transgender person 076 Progressive neurologic disorder 077 Received inactivated or unknown measles vaccine between 1963-1967 078 Received killed or unknown Mumps vaccine before 1979 079 Encephalopathy not attributable to another identifiable cause within 7 days of administration of a previous dose of Tdap, DTP, or DTaP vaccine 080 Adverse reaction to vaccine component 081 Severe allergic reaction after previous dose of Polio 082 Severe allergic reaction after previous dose of Japanese Encephalitis 083 Severe allergic reaction after previous dose of Rotavirus 084 Severe allergic reaction after previous dose of Typhoid 085 Severe allergic reaction after previous dose of Influenza 086 Severe allergic reaction after previous dose of Pertussis 087 Severe allergic reaction after previous dose of Diphtheria 088 Severe allergic reaction after previous dose of Tetanus 089 Severe allergic reaction after previous dose of Varicella 090 Severe allergic reaction after previous dose of HPV 091 Severe allergic reaction after previous dose of Measles 092 Severe allergic reaction after previous dose of Mumps 093 Severe allergic reaction after previous dose of Rubella 094 Severe allergic reaction after previous dose of Pneumococcal 095 Severe allergic reaction after previous dose of Meningococcal 096 Severe allergic reaction after previous dose of Hepatitis A 097 Severe allergic reaction after previous dose of Hepatitis B 098 Severe allergic reaction after previous dose of Hib 099 Severe allergic reaction after previous dose of Yellow Fever 100 Severe allergic reaction after previous dose of live zoster 101 Allergic reaction to egg protein 102 Severe allergic reaction to gelatin 103 Severe allergic reaction to arginine 104 Allergic reaction to latex 105 Severe allergic reaction to chicken protein 106 Severe allergic reaction to gentamicin 107 Severe allergic reaction to neomycin 108 Severe allergic reaction to streptomycin 109 Severe allergic reaction to polymyxin B 110 Hypersensitivity to yeast 111 Hypersensitivity to the preservative 2-phenoxyethanol 112 Hypersensitivity to alum 113 Severe allergic reaction after previous dose of Rabies 114 End stage renal disease 115 Severe allergic reaction to protamine sulfate 116 Severe allergic reaction after previous dose of Meningococcal B 117 Severe allergic reaction to diphtheria toxoid 118 Severe allergic reaction to tetanus toxoid 119 Severe allergic reaction after previous dose of cholera 120 Begin Date of antiviral therapy [ART] 121 Homelessness 122 Severe allergic reaction after previous dose of COVID-19 123 Severe allergic reaction after previous dose of Ebola 124 Severe allergic reaction to rice protein 125 Tetanus IG administration 126 Hep A IG administration 127 Hep B IG administration 128 Rabies IG administration 129 Varicella IG administration 130 Measles prophylaxis IG administration - Standard 131 Measles prophylaxis IG administration - Immunocompromised Contact 132 RBC [adenine-saline added] blood transfusion 133 Packed RBC blood transfusion 134 Whole blood transfusion 135 Plasma/platelet products blood transfusion 136 Cytomegalovirus IGIV 137 IGIV - Replacement therapy for immune deficiencies 138 IGIV - Immune thrombocytopenic purpura treatment 139 IGIV - Postexposure varicella prophylaxis 140 IGIV - Immune thrombocytopenic purpura treatment 141 IGIV - Kawasaki disease 142 Travel to or working in countries that have high or intermediate endemicity of Hepatitis A 143 Travel to areas or countries where polio is epidemic or endemic 144 International travel with possible contact with animals in areas where rabies is enzootic and immediate access to appropriate medical care might be limited 145 B-lymphocyte [humoral] - Severe antibody deficiencies 146 B-lymphocyte [humoral] - Less severe antibody deficiencies 147 T-lymphocyte [cell-mediated and humoral] - Complete defects 148 T-lymphocyte [cell-mediated and humoral] - Partial defects 149 T-lymphocyte [cell-mediated and humoral] - interferon-gamma/Interleukin 12 axis deficiencies 150 T-lymphocyte [cell-mediated and humoral] - interferon-gamma or interferon-alpha 151 Persistent complement, properdin, or factor B deficiency 152 Phagocytic function - Chronic granulomatous disease 153 Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency 154 HIV/AIDS - severely immunocompromised 155 HIV/AIDS - not severely immunocompromised 156 Generalized malignant neoplasm 157 Transplantation 158 Immunosuppressive therapy 159 Radiation therapy 160 Anatomical or functional asplenia 161 Chronic kidney disease 162 Travel to areas at risk for Yellow Fever transmission 163 Travel to areas in which there is a recognized risk of exposure to S. typhi 164 Travel to or are residents of countries in which meningococcal disease is hyperendemic or epidemic 165 Longer-term (e.g., 1 month or more) travel to a JE-endemic area 166 Travel to countries with high or intermediate prevalence of chronic HBV infection 167 Nephrotic Syndrome 168 Chemotherapy 169 History of sexual abuse or assault 170 Onset of pregnancy 171 Date of hematopoietic stem cell transplant 172 Severe allergic reaction after previous dose of recombinant zoster 173 Moving to JE-endemic country to take up residence 174 Frequent travel to JE-endemic areas 175 Patient seeks Hepatitis A protection 176 Patient seeks Hepatitis B protection 177 Patient seeks Meningococcal B protection 178 Leukemia 179 Lymphoma 180 Hodgkin's disease 181 Multiple myeloma 182 Ebola virus outbreak response 183 Health care personnel at federally designated Ebola treatment center in U.S. 184 Laboratorians or other staff at biosafety level 4 facilities in U.S. 185 Persons in settings that provide services to adults with high proportion of those persons have risk factors for HAV infection 186 HIV Infection 187 Allergic reaction to polysorbate 80 188 Known allergy to Polyethylene glycol [PEG] 189 Active treatment for solid tumors 190 Active treatment for hematologic malignancies 191 Receipt of CAR-T-cell therapy 192 Severe allergic reaction after previous dose of any egg-based IIV or LAIV influenza vaccine 193 Severe allergic reaction after previous dose of any ccIIV influenza vaccine 194 Severe allergic reaction after previous dose of any RIV influenza vaccine 195 Occupations at increased risk for COVID-19 exposure and transmission 196 Residing in an institutional setting at increased risk for COVID-19 exposure and transmission 197 Resident of a long term care facility 198 Cancer 199 Interstitial lung disease 200 Cystic fibrosis 201 Pulmonary hypertension 202 Dementia 203 Down syndrome 204 Obesity 205 Thalassemia 206 Cerebrovascular disease 207 Substance use disorder 208 Mental Health conditions 209 History of thrombosis with thrombocytopenia following the Janssen COVID-19 Vaccine or any other adenovirus-vectored COVID-19 vaccines 210 Severe allergic reaction after previous dose of Dengue vaccine 211 Evidence of previous dengue infection and living in areas where dengue is endemic 212 Health care personnel involved in the care and transport of patients with suspected or confirmed Ebola virus disease at Special Pathogen Treatment Centers 213 Laboratorians and support staff members at Laboratory Response Network (LRN) facilities that handle specimens that might contain replication-competent Ebola virus in the United States 214 Chronic obstructive pulmonary disease 215 Emphysema 216 Iatrogenic Immunosuppression 217 Persons working in rabies vaccine production facilities 218 Persons performing testing for rabies in diagnostic laboratories 219 Persons who frequently handle bats 220 Persons who frequently have contact with bats 221 Persons who frequently enter high-density bat environments 222 Persons who frequently perform animal necropsies 223 Severe allergic reaction after previous dose of orthopoxvirus vaccine 224 History or presence of atopic dermatitis 225 Household contact with history or presence of atopic dermatitis 226 Active exfoliative skin conditions 227 Household contact with active exfoliative skin conditions 228 Household contact is pregnant 229 Age is less than 1 year 230 Household contact who is less than 1 year of age 231 3 or more known major cardiac risk factors 232 Research laboratory personnel working with more virulent orthopoxviruses (e.g., Variola virus or mpox virus) 233 Clinical laboratory personnel performing diagnostic testing for more virulent orthopoxviruses (e.g., Variola virus or mpox virus) 234 Designated response team members working with more virulent orthopoxviruses (e.g., Variola virus or mpox virus) 235 Healthcare personnel who care for patients infected with more virulent orthopoxviruses (e.g., Variola virus or mpox virus) 236 Research laboratory personnel working with less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus) 237 Clinical laboratory personnel performing diagnostic testing for less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus) 238 Designated response team members working with less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus) 239 Healthcare personnel who administer ACAM2000 240 Healthcare personnel who care for patients infected with less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus) 241 Known exposure to mpox 242 Presumed exposure to mpox 243 Lack of laboratory confirmation of a previous Dengue infection 244 Severe allergic reaction after previous dose of RSV vaccine 245 American Indian or Alaskan Native 246 Severe immunocompromise 247 Gay, bisexual, and other men who have sex with men, transgender or nonbinary peope who in the past 6 months have had one of the following: 1) A new diagnosis of ≥ 1 sexually transmitted disease 2) More than one sex partner 3) Sex at a commercial sex venue 4) Sex in association with a large public event in a geographic area where mpox transmission is occurring 248 Sexual partners of gay, bisexual, and other men who have sex with men, transgender or nonbinary peope who in the past 6 months have had one of the following: 1) A new diagnosis of ≥ 1 sexually transmitted disease 2) More than one sex partner 3) Sex at a commercial sex venue 4) Sex in association with a large public event in a geographic area where mpox transmission is occurring 249 Moving or traveling to an area where TBE is endemic and will have extensive exposure to ticks because of their planned outdoor activities and itinerary 250 Moving or traveling to an area where TBE is endemic who might engage in outdoor activities in areas where ticks are likely to be found 251 Laboratory workers with a potential for exposure to TBE virus 252 Severe allergic reaction after previous dose of Tick-borne Encephalitis vaccine
Observations and Conditions that are important to indications or contraindications in vaccine forecasting
Recipient of a hematopoietic stem cell transplant
Travel to an area of active cholera transmission
Family history of altered immunocompetence
Laboratory Evidence of Immunity or confirmation of Hepatitis A disease
Laboratory Evidence of Immunity or confirmation of Hepatitis B disease
Laboratory Evidence of Immunity for Measles
Laboratory Evidence of Immunity for Mumps
Laboratory Evidence of Immunity for Rubella
Laboratory Evidence of Immunity or confirmation of Varicella disease
Healthcare provider verified history of or diagnosis of Varicella
Healthcare provider verified history or diagnosis of Herpes Zoster
Persons with perinatal HIV infection who do not have evidence of severe immunosuppression and who were vaccinated with MMR before establishment of antiviral therapy [ART]
Taken influenza antiviral medications within the previous 48 hours
Antimicrobial or antimalarial taken within 72 hours
Not in a long-term, mutually monogamous relationship
Sex partner of Hepatitis B surface antigen-positive persons
Anticipate close personal contact with international adoptee
Travel to country with a Yellow Fever vaccination entry requirement
College students living in residence halls
Resident of area at risk for exposure to the disease
Working with Hepatitis A virus in research setting
Microbiologists routinely exposed to Neisseria meningitidis
Microbiology laboratorians who work frequently with S. typhi
Laboratory personnel who might be exposed to YFV
Laboratory workers who handle specimens that might contain polioviruses
Health-care workers who have close contact with patients who might be excreting wild polioviruses
Public safety worker exposed to blood or infection body fluids
Staff of institution for persons with developmental disabilities
Persons whose activities bring them into frequent contact with rabies virus or potentially rabid animals
Client of institution for persons with developmental disabilities
In drug abuse treatment and prevention facility
Household contact with hepatitis B surface antigen-positive persons
Intimate exposure to a documented S. typhi carrier
Household and close contacts of immunocompromised persons
Negative serological screening for varicella
Received inactivated or unknown measles vaccine between 1963-1967
Received killed or unknown Mumps vaccine before 1979
Encephalopathy not attributable to another identifiable cause within 7 days of administration of a previous dose of Tdap, DTP, or DTaP vaccine
Severe allergic reaction after previous dose of Polio
Severe allergic reaction after previous dose of Japanese Encephalitis
Severe allergic reaction after previous dose of Rotavirus
Severe allergic reaction after previous dose of Typhoid
Severe allergic reaction after previous dose of Influenza
Severe allergic reaction after previous dose of Pertussis
Severe allergic reaction after previous dose of Diphtheria
Severe allergic reaction after previous dose of Tetanus
Severe allergic reaction after previous dose of Varicella
Severe allergic reaction after previous dose of HPV
Severe allergic reaction after previous dose of Measles
Severe allergic reaction after previous dose of Mumps
Severe allergic reaction after previous dose of Rubella
Severe allergic reaction after previous dose of Pneumococcal
Severe allergic reaction after previous dose of Meningococcal
Severe allergic reaction after previous dose of Hepatitis A
Severe allergic reaction after previous dose of Hepatitis B
Severe allergic reaction after previous dose of Hib
Severe allergic reaction after previous dose of Yellow Fever
Severe allergic reaction after previous dose of live zoster
Severe allergic reaction to chicken protein
Severe allergic reaction to streptomycin
Hypersensitivity to the preservative 2-phenoxyethanol
Severe allergic reaction after previous dose of Rabies
Severe allergic reaction to protamine sulfate
Severe allergic reaction after previous dose of Meningococcal B
Severe allergic reaction to diphtheria toxoid
Severe allergic reaction to tetanus toxoid
Severe allergic reaction after previous dose of cholera
Severe allergic reaction after previous dose of COVID-19
Severe allergic reaction after previous dose of Ebola
Severe allergic reaction to rice protein
Measles prophylaxis IG administration - Standard
Measles prophylaxis IG administration - Immunocompromised Contact
RBC [adenine-saline added] blood transfusion
Plasma/platelet products blood transfusion
IGIV - Replacement therapy for immune deficiencies
IGIV - Immune thrombocytopenic purpura treatment
IGIV - Postexposure varicella prophylaxis
Travel to or working in countries that have high or intermediate endemicity of Hepatitis A
Travel to areas or countries where polio is epidemic or endemic
International travel with possible contact with animals in areas where rabies is enzootic and immediate access to appropriate medical care might be limited
B-lymphocyte [humoral] - Severe antibody deficiencies
B-lymphocyte [humoral] - Less severe antibody deficiencies
T-lymphocyte [cell-mediated and humoral] - Complete defects
T-lymphocyte [cell-mediated and humoral] - Partial defects
T-lymphocyte [cell-mediated and humoral] - interferon-gamma/Interleukin 12 axis deficiencies
T-lymphocyte [cell-mediated and humoral] - interferon-gamma or interferon-alpha
Persistent complement, properdin, or factor B deficiency
Phagocytic function - Chronic granulomatous disease
Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency
HIV/AIDS - not severely immunocompromised
Travel to areas at risk for Yellow Fever transmission
Travel to areas in which there is a recognized risk of exposure to S. typhi
Travel to or are residents of countries in which meningococcal disease is hyperendemic or epidemic
Longer-term (e.g., 1 month or more) travel to a JE-endemic area
Travel to countries with high or intermediate prevalence of chronic HBV infection
Date of hematopoietic stem cell transplant
Severe allergic reaction after previous dose of recombinant zoster
Moving to JE-endemic country to take up residence
Patient seeks Meningococcal B protection
Health care personnel at federally designated Ebola treatment center in U.S.
Laboratorians or other staff at biosafety level 4 facilities in U.S.
Persons in settings that provide services to adults with high proportion of those persons have risk factors for HAV infection
Known allergy to Polyethylene glycol [PEG]
Active treatment for hematologic malignancies
Severe allergic reaction after previous dose of any egg-based IIV or LAIV influenza vaccine
Severe allergic reaction after previous dose of any ccIIV influenza vaccine
Severe allergic reaction after previous dose of any RIV influenza vaccine
Occupations at increased risk for COVID-19 exposure and transmission
Residing in an institutional setting at increased risk for COVID-19 exposure and transmission
History of thrombosis with thrombocytopenia following the Janssen COVID-19 Vaccine or any other adenovirus-vectored COVID-19 vaccines
Severe allergic reaction after previous dose of Dengue vaccine
Evidence of previous dengue infection and living in areas where dengue is endemic
Health care personnel involved in the care and transport of patients with suspected or confirmed Ebola virus disease at Special Pathogen Treatment Centers
Laboratorians and support staff members at Laboratory Response Network (LRN) facilities that handle specimens that might contain replication-competent Ebola virus in the United States
Persons working in rabies vaccine production facilities
Persons performing testing for rabies in diagnostic laboratories
Persons who frequently have contact with bats
Persons who frequently enter high-density bat environments
Persons who frequently perform animal necropsies
Severe allergic reaction after previous dose of orthopoxvirus vaccine
History or presence of atopic dermatitis
Household contact with history or presence of atopic dermatitis
Household contact with active exfoliative skin conditions
Household contact who is less than 1 year of age
3 or more known major cardiac risk factors
Research laboratory personnel working with more virulent orthopoxviruses (e.g., Variola virus or mpox virus)
Clinical laboratory personnel performing diagnostic testing for more virulent orthopoxviruses (e.g., Variola virus or mpox virus)
Designated response team members working with more virulent orthopoxviruses (e.g., Variola virus or mpox virus)
Healthcare personnel who care for patients infected with more virulent orthopoxviruses (e.g., Variola virus or mpox virus)
Research laboratory personnel working with less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus)
Clinical laboratory personnel performing diagnostic testing for less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus)
Designated response team members working with less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus)
Healthcare personnel who administer ACAM2000
Healthcare personnel who care for patients infected with less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus)
Lack of laboratory confirmation of a previous Dengue infection
Severe allergic reaction after previous dose of RSV vaccine
Gay, bisexual, and other men who have sex with men, transgender or nonbinary peope who in the past 6 months have had one of the following: 1) A new diagnosis of ≥ 1 sexually transmitted disease 2) More than one sex partner 3) Sex at a commercial sex venue 4) Sex in association with a large public event in a geographic area where mpox transmission is occurring
Sexual partners of gay, bisexual, and other men who have sex with men, transgender or nonbinary peope who in the past 6 months have had one of the following: 1) A new diagnosis of ≥ 1 sexually transmitted disease 2) More than one sex partner 3) Sex at a commercial sex venue 4) Sex in association with a large public event in a geographic area where mpox transmission is occurring
Moving or traveling to an area where TBE is endemic and will have extensive exposure to ticks because of their planned outdoor activities and itinerary
Moving or traveling to an area where TBE is endemic who might engage in outdoor activities in areas where ticks are likely to be found
Laboratory workers with a potential for exposure to TBE virus
Severe allergic reaction after previous dose of Tick-borne Encephalitis vaccine